For Adults:

If you struggle with
treatment-resistant depression,
there's a different choice to turn to.


SPRAVATO® is the first nasal spray medication, taken along with an oral antidepressant, for adults with treatment-resistant depression (TRD).

If you’ve struggled with depression and tried two or more antidepressants* in your current episode without adequate relief, talk to your healthcare provider to see if you have treatment-resistant depression.

*Of adequate dose and duration.

Ask your doctor if SPRAVATO® may be an option for you.


In a clinical study of adults with 
treatment-resistant depression:

Those who took SPRAVATO® and an oral antidepressant experienced greater reductions of depression symptoms at four weeks compared to those who received a placebo plus an oral antidepressant.

Based on an overall score on a standardized rating scale.

Most common side effects of SPRAVATO®:

Dissociation, dizziness, nausea, sedation, spinning sensation, reduced sense of touch and sensation, anxiety, lack of energy, increased blood pressure, vomiting and feeling drunk.

If these common side effects occur, they usually happen right after taking SPRAVATO® and go away the same day.

These are not all the possible side effects of SPRAVATO®. Learn more about possible side effects here.

SPRAVATO® is only available at certified SPRAVATO® treatment centers under the supervision of a healthcare provider.

Because of the risks for sedation, dissociation and abuse and misuse, your healthcare provider will enroll you in the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program.


Robin P., Berkeley, California:

Robin is a real patient with treatment-resistant depression and has been compensated for her time by Janssen Pharmaceuticals, Inc.

“When you’re depressed, you forget about the little things you used to enjoy. I’ve been doing a lot of catching up now that I’m feeling better.”

Individual results may vary.

SPRAVATO® works differently than other medications to target treatment-resistant depression.

SPRAVATO® is taken with an oral antidepressant.

Frequently Asked Questions

Healthcare providers may define the term treatment-resistant depression differently. In the SPRAVATO® clinical trials, treatment-resistant depression was defined as adults who are currently struggling with major depressive disorder and have not responded adequately to at least two different antidepressants of adequate dose and duration in the current episode.

SPRAVATO® (esketamine) CIII nasal spray is a prescription medicine, taken along with an oral antidepressant, for treatment-resistant depression (TRD) in adults.

Talk to your healthcare provider to see if SPRAVATO® may be right for you. SPRAVATO® is a prescription medicine given by nasal spray and taken with an oral antidepressant to improve the symptoms of depression in adults who have treatment-resistant depression. Be sure to tell your healthcare provider if you have a history of abusing prescription or street drugs, or a problem with alcohol. You should also tell your healthcare provider if you are pregnant, planning to become pregnant, are breastfeeding or planning to breastfeed. You should not take SPRAVATO® if you are pregnant. You should not breastfeed if you are taking SPRAVATO®. Do not take SPRAVATO® if you have a blood vessel disease (aneurysm), an abnormal connection between your blood vessels (arteriovenous malformation), a history of bleeding in the brain or are allergic to esketamine, ketamine or any of the ingredients in SPRAVATO®. Talk to your healthcare provider about all of your health conditions and medications when discussing treatment with SPRAVATO®.